CYRX
NASDAQ · Life Sciences Tools & Services
Cryoport Inc
$8.52
+0.24 (+2.90%)
Financial Highlights (FY 2026)
Revenue
239.16M
Net Income
-120,172,624
Gross Margin
43.6%
Profit Margin
-50.3%
Rev Growth
+0.9%
D/E Ratio
0.50
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 43.6% | 43.6% | 39.0% | 39.0% |
| Operating Margin | -49.2% | -44.3% | 22.9% | 18.0% |
| Profit Margin | -50.3% | -47.7% | 14.0% | 17.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 239.16M | 237.12M | 137.31M | 144.41M |
| Gross Profit | 104.32M | 103.43M | 53.62M | 56.39M |
| Operating Income | -117,667,613 | -104,997,870 | 31.39M | 25.95M |
| Net Income | -120,172,624 | -107,233,156 | 19.23M | 25.18M |
| Gross Margin | 43.6% | 43.6% | 39.0% | 39.0% |
| Operating Margin | -49.2% | -44.3% | 22.9% | 18.0% |
| Profit Margin | -50.3% | -47.7% | 14.0% | 17.4% |
| Rev Growth | +0.9% | +0.9% | +13.1% | +7.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 72.41M | 72.41M | 221.73M | 216.61M |
| Total Equity | 144.64M | 144.64M | 262.41M | 301.43M |
| D/E Ratio | 0.50 | 0.50 | 0.84 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -92,684,958 | -87,299,930 | 43.82M | 47.91M |
| Free Cash Flow | — | — | 11.97M | 10.29M |